AVTR Avantordata gap · 86% coverage
Health Care · Life Sciences Tools & Services · close $16.42 (2026-10-16) · latest quarter in EDGAR: 2026-03-31
Avantor (AVTR) has a ThetaGrade House Rating of 30/100 (grade F), ranking #146 of 150 in Health Care. Its strongest pillars are valuation (83) and cash flow (53); its weakest is balance sheet (13). Data gap: 3 factors without usable data, so 86% of the method weight is covered. TTM revenue growth is -2.0% and operating margin -4.5%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, P/E (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 86% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 17| Revenue growth YoY (TTM) (13.3%) | -2.0% | 5 |
| EPS growth YoY (TTM) (13.3%) | -177.9% | 4 |
| Revenue acceleration (6.7%) | 1.4% | 65 |
Profitability
weight 18.5% (→20.0%) · 20| Operating margin (10.7%) | -4.5% | 20 |
| 4Q gross-margin change (9.3%) | -1.4% | 21 |
Balance sheet
weight 18.5% (→20.0%) · 13| Net debt / EBITDA (10.7%) | 30.47× | 0 |
| Current ratio (5.3%) | 1.76 | 34 |
| Interest coverage (4.0%) | -1.73× | 19 |
Cash flow
weight 12.33% (→13.3%) · 53| FCF margin (6.7%) | 7.6% | 38 |
| FCF yield (6.7%) | 4.4% | 67 |
Valuation
weight 12.33% (→13.3%) · 83| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (13.3%) | 2.25× | 83 |
Technicals (EOD)
| RSI(14) | 68.4 |
| EMA 9 / 21 | 15.78 / 15.47 |
| 200-day SMA | 10.96 |
| Volume vs 20d avg | 3.52× |
| 20-day return | 3.5% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITFundamental miss: revenue growth negative YoY
- EXITBalance-sheet stress: net debt/EBITDA above 4×
Data source per metric (SEC XBRL tag or derivation): Revenue: Revenues · Gross profit: GrossProfit · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like AVTR's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is AVTR's House Rating?
- AVTR scores 30 out of 100 (grade F) as of 2026-10-16, ranking #146 of 150 Health Care stocks we cover.
- What do analysts say about AVTR?
- We do not have enough analyst-sentiment data to score this stock.
- When does AVTR report earnings next?
- AVTR's next earnings report is estimated for about 2026-10-28 (window 2026-10-23 to 2026-11-02), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is AVTR a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology